硫酶
内科学
内分泌学
泌尿系统
酮体
异亮氨酸
突变
分解代谢
先天性代谢错误
医学
新陈代谢
化学
生物
生物化学
氨基酸
基因
亮氨酸
受体
过氧化物酶体
作者
Toshiyuki Fukao,Genxi Zhang,Nobuo Sakura,T Kubo,H. Yamaga,Akihiro Hazama,Yusuke Kohno,Naoki Matsuo,Masahiro Kondo,Seiji Yamaguchi,Yosuke Shigematsu,N Kondo
标识
DOI:10.1023/a:1025117226051
摘要
Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency is an inborn error of metabolism affecting isoleucine and ketone bodies in the catabolic process. Mutation analysis and expression analysis of mutant cDNAs have facilitated the division of T2-deficient patients into two groups: those with null mutations in either allele (group 1) and those with mutation(s) retaining some residual T2 activity in at least one of two mutant alleles (group II). Among 5 Japanese T2-deficient patients, GK01 belonged to group I and the other patients (GK19, GK19B, GK30 and GK31) to group II. As we have suggested previously, the severity of ketoacidotic episodes in the group II patients was similar to that in the group I patient. However, the urinary organic acid and blood spot acylcarnitine profiles under stable conditions differed between the two groups. The group I patient had typical profiles for the T2 deficiency. In contrast, in all four patients in group II, tiglylglycine was not or was only faintly detected and the 2-methyl-3-hydroxybutyrate levels were less than the cutoff value. Their tiglylcarnitine levels were within the normal range and 2-methyl-3-hydroxy-, butyrylcarnitine was detected just around the cutoff value in our newborn screening pilot test. Hence, these analyses under stable conditions are not reliable for diagnosing the T2 deficiency in the group II patients. The T2 deficiency (group II) can be misdiagnosed as normal if these analyses are performed under nonepisodic conditions and possibly during the newborn screening for inborn errors of metabolism.
科研通智能强力驱动
Strongly Powered by AbleSci AI